胎盘多肽注射液联合雷替曲塞与奥沙利铂治疗晚期结肠癌临床研究

Clinical Study on Placenta Polypeptide Injection Combined with Raltitrexed and Oxaliplatin in the Treatment of Advanced Colon Cancer

目的探讨胎盘多肽注射液联合雷替曲塞与奥沙利铂治疗晚期结肠癌的临床疗效及安全性。方法选取医院2016年8月至2018年1月收治的晚期结肠癌患者95例,随机分为对照组(47例)和治疗组(48例)。对照组给予m FOLFOX6化疗方案,治疗组给予胎盘多肽注射液联合雷替曲塞与奥沙利铂,均治疗6个疗程。结果治疗组的疾病控制率为93.75%,显著高于对照组的76.60%(χ^2=5.562,P=0.018<0.05);两组治疗后的血清糖类抗原199(CA199)、癌胚抗原(CEA)水平均明显低于治疗前,且治疗组的变化幅度大于对照组(P<0.05);两组治疗后的CD4^+,CD8^+,CD4^+/CD8^+水平均明显低于治疗前,且治疗组明显高于对照组(P<0.05);治疗组的不良反应发生率为18.75%,显著低于对照组的46.81%(χ^2=8.505,P=0.004<0.05);治疗组的生活质量改善率为85.42%,显著高于对照组的63.83%(χ^2=5.861,P=0.015<0.05)。结论胎盘多肽注射液联合雷替曲塞与奥沙利铂治疗晚期结肠癌的临床疗效显效,且安全性较好,值得临床推广。

Objective To investigate the clinical efficacy and safety of Placenta Polypeptide Injection combined with raltitrexed and oxaliplatin in the treatment of advanced colon cancer. Methods Totally 95 patients with advanced colon cancer admitted to our hospital from August 2016 to January 2018 were selected and randomly divided into the control group( n = 47) and the treatment group( n = 48).The patients in the control group were given m FOLFOX6 chemotherapy regimen,while the patients in the treatment group were given Placenta Polypeptide Injection combined with raltitrexed and oxaliplatin. All patients were treated for 6 courses. Results The disease control rate of the treatment group was 93. 75%,which was significantly higher than 76. 60% of the control group( χ2 = 5. 562,P =0. 018 < 0. 05). After treatment,the levels of serum carbohydrate antigen 199( CA199) and carcinoembryonic antigen( CEA) in the two groups were significantly lower than those before treatment,and the change in the treatment group was more significant than that in the control group( P < 0. 05). After treatment,the levels of CD4+,CD8+,CD4+/CD8+in the two groups were significantly lower than those before treatment,and those in the treatment group were significantly higher than those in the control group( P < 0. 05). The incidence of adverse reactions in the treatment group was 18. 75%,which was significantly lower than 46. 81% in the control group( χ2 = 8. 505,P = 0. 004 < 0. 05). The improvement rate of quality of life in the treatment group was 85. 42%,which was significantly higher than63. 83% in the control group( χ2 = 5. 861,P = 0. 015 < 0. 05). Conclusion Placenta Polypeptide Injection combined with raltitrexed and oxaliplatin is effective and safe in the treatment of advanced colon cancer,which is worthy of clinical promotion.